HUTCHMED (China) Ltd
HCM15.180USD
+0.610+4.19%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
13.24BMarket Cap
28.07P/E TTM
More Details of HUTCHMED (China) Ltd Company
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
HUTCHMED (China) Ltd Info
Ticker SymbolHCM
Company nameHUTCHMED (China) Ltd
IPO dateMay 19, 2006
CEOCheng (Chig Fung)
Number of employees1811
Security typeDepository Receipt
Fiscal year-endMay 19
Address48th Floor, Cheung Kong Center, 2 Queen's Road Central
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryHong Kong
Postal code- -
Phone85221281188
Websitehttps://www.hutch-med.com/
Ticker SymbolHCM
IPO dateMay 19, 2006
CEOCheng (Chig Fung)
Company Executives of HUTCHMED (China) Ltd
Name
Name/Position
Position
Shareholding
Change
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Mr. Charles George Rupert Nixon
Mr. Charles George Rupert Nixon
Group General Counsel
Group General Counsel
--
--
Dr. Ming (Michael) Shi, Ph.D.
Dr. Ming (Michael) Shi, Ph.D.
Executive Vice President, Head - Research and Development and Chief Medical Officer
Executive Vice President, Head - Research and Development and Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
Other
97.71%
Shareholders
Shareholders
Proportion
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
Other
97.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
2.30%
Investment Advisor
0.65%
Research Firm
0.22%
Hedge Fund
0.13%
Bank and Trust
0.03%
Sovereign Wealth Fund
0.01%
Other
96.66%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
143
5.89M
3.38%
-5.77M
2025Q3
144
6.22M
3.56%
-5.80M
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Schroder Investment Management (Singapore) Ltd.
1.69M
0.97%
-84.85K
-4.78%
Sep 30, 2025
Allianz Global Investors Asia Pacific Limited
863.00K
0.49%
-15.73K
-1.79%
Sep 30, 2025
Schroder Investment Management (Hong Kong) Ltd.
778.26K
0.45%
-27.37K
-3.40%
Sep 30, 2025
Jane Street Capital, L.L.C.
340.34K
0.2%
+164.38K
+93.42%
Sep 30, 2025
State Street Investment Management (US)
317.50K
0.18%
-11.29K
-3.43%
Sep 30, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Sep 30, 2025
Amundi Asset Management, SAS
223.33K
0.13%
+65.90K
+41.86%
Sep 30, 2025
M&G Investment Management Ltd.
204.43K
0.12%
-55.19K
-21.26%
Sep 30, 2025
Renaissance Technologies LLC
131.00K
0.08%
+2.00K
+1.55%
Sep 30, 2025
Saint Olive Gestion
100.00K
0.06%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
0.78%
National Security Emerging Markets Index ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Tema Oncology ETF
Proportion0.78%
National Security Emerging Markets Index ETF
Proportion0.35%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
Proportion0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
Proportion0%
ActivePassive International Equity ETF
Proportion0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
